Rituximab is superior to mycophenolate mofetil in the management of patients with moderate to severe pemphigus vulgaris, a new study shows. A phase 3 international trial, published in the NEJM, randomised 135 patients to either IV rituximab or oral mycophenolate, in addition to oral prednisone tapered to discontinuation by 24 weeks. The US-led study found ...
Two trials compare treatments for pemphigus vulgaris
By Mardi Chapman
4 Jun 2021